Фармакогенетика антипсихотик-индуцированных метаболических нарушений: актуальное состояние проблемы
Аннотация
Об авторах
Регина Фаритовна Насырова
Санкт-Петербургский научно-исследовательский психоневрологический институт им. В.М. Бехтерева
Россия
Россия
Наталья Александровна Сивакова
Санкт-Петербургский научно-исследовательский психоневрологический институт им. В.М. Бехтерева
Россия
Россия
Дмитрий Владимирович Иващенко
Санкт-Петербургский научно-исследовательский психоневрологический институт им. В.М. Бехтерева
Россия
Россия
Дмитрий Николаевич Сосин
Санкт-Петербургский научно-исследовательский психоневрологический институт им. В.М. Бехтерева
Россия
Россия
Евгений Евгеньевич Ершов
СПб ГБУЗ «Психиатрическая больница №1 им. П.П. Кащенко»
Россия
Россия
Кристина Анатольевна Сосина
Санкт-Петербургский научно-исследовательский психоневрологический институт им. В.М. Бехтерева
Россия
Россия
Лилия Шамильевна Ахметова
Казанский государственный медицинский университет
Россия
Россия
Ольга Владимировна Воликова
Алтайский государственный медицинский университет
Россия
Россия
Тангюль Загировна Бейбалаева
Казанский государственный медицинский университет
Россия
Россия
Николай Григорьевич Незнанов
Санкт-Петербургский научно-исследовательский психоневрологический институт им. В.М. Бехтерева
Россия
Россия
Список литературы
1. Алфимов П.В., Рывкин П.В., Ладыженский М.Я., Мосолов С.Н. Метаболический синдром у больных шизофренией (обзор литературы) // Современная терапия психических расстройств - 2014. - № 3. - С. 8-14. / Alfimov P.V., Ryvkin P.V., Ladyzhensky M.Ya., Mosolov S.N. [Metabolic syndrome in schizophrenic pateints (literature review)]. Sovremennaya terapiya psikhicheskikh rasstroystva [Modern Therapy of Mental Disorders]. 2014; 3: 8-14. (In Russ.).
2. Иващенко Д.В., Сосин Д.Н., Кирничная К.А., Ершов Е.Е., Иванов М.В., Тараскина А.Е., Аточин Д.Н., Насырова РФ., Незнанов Н.Г. Центральные и периферические механизмы реализации антипсихотик-индуцированного набора веса // Обозрение психиатрии и медицинской психологии им. В.М. Бехтерева. - 2015. - № 1. - С. 3-10.
3. Мосолов С.Н. Биологичекие методы терапии психических расстройств / Доказательная медицина - клинической практике // Москва, 2012. -1078 с.
4. Adkins D.E., Aberg K., McClay J.L., Bukszar J., Zhao Z., Jia P. et al. Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs / Mol Psychiatry 2010; 16: 321-332.
5. Alp Üçok, Wolfgang Gaebel. Side effects of atypical antipsychotics: a brief overview // World Psychiatry. - 2008 Feb. - Vol. 7(1). - P. 58-62.
6. Arranz M.J., de Leon J. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research // Mol. Psychiatry. - 2007. - Vol. 12(8). - P. 707-747.
7. Boulton D.W., DeVane C.L., Liston H.L., Markowitz J.S. In vitro P-glycoprotein affinity for atypical and conventional antipsychotics // Life Sci. - 2002. - Vol. 71(2). - P. 163-169.
8. Brandl E.J., Frydrychowicz C., Tiwari A.K., Lett T.A., Kitzrow W., Büttner S., Ehrlich S., Meltzer H.Y., Lieberman J.A., Kennedy J.L., Müller D.J., Puls I. Association study of polymorphisms in leptin and leptin receptor genes with antipsychotic-induced body weight gain // Prog. Neuropsychopharmacol Biol. Psychiatry. - 2012. - Vol. 38(2). - P. 134-141.
9. Cabaleiro T., Lopez-Rodriguez R., Ochoa D., Român M., Novalbos J., Abad-Santos F. Polymorphisms influencing olanzapine metabolism and adverse effects in healthy subjects // Hum Psychopharmacol. - 2013. - Vol. 28(3). - P. 205-214.
10. Coutts R.T., Urichuk L.J. Polymorphic cytochromes P450 and drugs used in psychiatry // Cell Mol Neurobiol. -1999. - Vol. 19. - P. 325-355.
11. Czerwensky F., Leucht S., Steimer W. MC4R rs489693: a clinical risk factor for second generation antipsychotic-related weight gain? // Int. J. Neuropsychopharmacol. - 2013. - Vol. 16(9). - P. 2103-2109.
12. De Luca V., Mueller D.J., de Bartolomeis A., Kennedy J.L. Association of the HTR2C gene and antipsychotic induced weight gain: a meta-analysis // Int. J. Neuropsychopharmacol. -2007. - Vol. 10(5). - P. 697-704.
13. De Luca V., Souza R.P., Viggiano E., Sickert L., Teo C., Zai C., Tiwari A.K., Müller D.J., Lieberman J.A., Volavka J., Meltzer H.Y., Kennedy J.L. Genetic interactions in the adrenergic system genes: analysis of antipsychotic-induced weight gain // Hum Psychopharmacol. - 2011. - Vol. 26(6). - P. 386-91.
14. De Miranda D.M., Mamede M., de Souza B.R., et al. Molecular medicine: a path towards a personalized medicine // Rev. Bras. Psiquiatr. - 2012. - Vol. 34(1). - P. 82-91.
15. Eichelbaum M., Evert B. Influence of pharmacogenetics on drug disposition and response // Clin. Exp. Pharmacol. Physiol. - 1996. - Vol. 23 - P. 983-985.
16. Ellingrod V.L., Bishop J.R., Moline J., Lin Y.C., Miller D.D. “Leptin and leptin receptor gene polymorphisms and increases in body mass index (BMI) from olanzapine treatment in persons with schizophrenia // Psychopharmacol. Bull. - 2007. - Vol. 40(1). - P. 57-62.
17. Ellingrod V.L., Perry P.J., Ringold J.C., Lund B.C., Bever-Stille K., Fleming F., Holman T.L., Miller D. “Weight gain associated with the -759C/T polymorphism of the 5HT2C receptor and olanzapine”// Am J Med Genet B Neuropsychiatr Genet. - 2005 Apr 5. - 134B(1):76-8.
18. Ellingrod V.L., Miller D., Schultz S.K., Wehring H., Arndt S. “CYP2D6 polymorphisms and atypical antipsychotic weight gain”// Psychiatr Genet. - 2002. - Vol. 12(1) - P. 55-58.
19. Eva J. Brandl, M.D.; James L. Kennedy, M.D., FRCPC; Daniel J Müller, MD, PhD. Pharmacogenetics of Antipsychotics // Can. J. Psychiatry. - 2014. - Vol. 59(2) - P. 76-88.
20. Farooqi I.S., O’Rahilly S. Monogenic obesity in humans // AnnuRevMed. - 2005. - Vol. 56. - P. 443-458.
21. Foster A., Miller D.D., Buckley P.F. Pharmacogenetics and schizophrenia// Psychiatr. Clin. North. Am. - 2007. - Vol. 30(3) - P. 417-435.
22. Godlewska B.R., Olajossy-Hilkesberger L., Ciwoniuk M., Olajossy M., Marmurowska-Michatowska H., Limon J., Landowski J. Olanzapine-induced weight gain is associated with the -759C/T and -697G/C polymorphisms of the HTR2C gene // Pharmacogenomics J. - 2009 Aug. - Vol. 9(4). - P. 234-241.
23. Graff M., Ngwa J.S., Workalemahu T., Homuth G., Schipf S., Teumer A., Völzke H., Wallaschofski H. et al. Genome-wide analysis of BMI in adolescents and young adults reveals additional insight into the effects of genetic loci over the life course // Hum. Mol. Genet. - 2013. - Vol. 22(17). - P. 3597-3607.
24. Gregoor J.G., van der Weide J., Loovers H.M., van Megen H.J., Egberts T.C., Heerdink E.R. Polymorphisms of the LEP, LEPR and HTR2C gene: obesity and BMI change in patients using antipsychotic medication in a naturalistic setting // Pharmacoge-nomics. - 2011. - Vol. 12(6). - P. 919-923.
25. Gunes A., Melkersson K.I., Scordo M.G., Dahl M.L. Association between HTR2C and HTR2A polymorphisms and metabolic abnormalities in patients treated with olanzapine or clozapine // J. Clin. Psychopharmacol. - 2009. - Vol. 29(1). - P. 65-68.
26. Hong C.J., Liou Y.J., Bai Y.M., Chen T.T., Wang Y.C., Tsai S.J. Dopamine receptor D2 gene is associated with weight gain in schizophrenic patients under long-term atypical antipsychotic treatment // Pharmacogenet. Genomics. - 2010. - Vol. 20(6). - P. 359-366.
27. Houston J.P., Kohler J., Bishop J.R., Ellingrod V.L., Ostbye K.M., Zhao F., Conley R.R., Poole Hoffmann V., Fijal B.A. Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia // J. Clin. Psychiatry. - 2012. - Vol. 73(8). - P. 1077-1086.
28. Hsiao D-J, Wu LS-H, Huang S-Y, Lin E. Weight loss and body fat reduction under sibutramine therapy in obesity with the C825T polymorphism in the GNB3 gene. Pharmacogenetics Genomics. - 2009. - Vol. 19. - P. 730-733.
29. Jagadish M.N., Fernandez C.S., Hewish D.R., Macaulay S.L., Gough K.H., Grusovin J. et al. Insulin-responsive tissues contain the core complex protein SNAP-25 (synaptosomal-associated protein 25) A and B isoforms in addition to syntaxin 4 and synaptobrevins 1 and 2. // J. Biochem. - 1996. - Vol. 317. - P. 945-954.
30. Jain K.K. Nanobiotechnology and personalized medicine // Prog. Mol. Biol. Transl. Sci. - 2011. - Vol. 104. - P. 325-54.
31. Kang S.G., Lee H.J., Park Y.M., Choi J.E., Han C., Kim Y.K., Kim S.H., Lee M.S., Joe S.H., Jung I.K., Kim L. Possible association between the -2548A/G polymorphism of the leptin gene and olanzapine-induced weight gain // Prog. Neuropsychopharmacol. Biol. Psychiatry. - 2008. - Vol. 32(1). - P. 160-163.
32. Kastelic M., Koprivsek J., Plesnicar B.K., et al. MDR1 gene polymorphisms and response to acute risperidone treatment // Prog. Neuropsychopharmacol. Biol. Psychiatry. - 2010.- 34(2). - P. 387392.
33. Kurose K., Sugiyama E., Saito Y. “Population differences in major functional polymorphisms of pharmacokinetics/pharmacodynamics-related genes in Eastern Asians and Europeans: implications in the clinical trials for novel drug development // Drug. Metab. Pharmacokinet. - 2012. - Vol. 27(1). - P. 9-54.
34. Kuzman M.R., Medved V., Bozina N., Hotujac L., Sain I., Bilusic H. The influence of 5-HT(2C) and MDR1 genetic polymorphisms on antipsychotic-induced weight gain in female shizofrenic patients // Psychiatry Res. - 2008. - Vol. 160(3). - P. 308315.
35. Lane H.Y., Liu Y.C., Huang C.L., Chang Y.C., Wu P.L., Lu C.T., Chang W.H. Risperidone-related weight gain: genetic and nongenetic predictors // J. Clin. Psychopharmacol. - 2006. - Vol. 26(2). - P. 128-34.
36. Le Hellard S., Theisen F.M., Haberhausen M., Raeder M.B., Ferno J., Gebhardt S. et al. Association between the insulin-induced gene 2 (INSIG2) and weight gain in a German sample of antipsychotictreated schizophrenic patients: perturbation of SREBP-controlled lipogenesis in drug-related metabolic adverse effects? // Mol. Psychiatry. - 2009. - Vol. 14. - P 308-317.
37. Lencz T., Malhotra A.K. Pharmacogenetics of antipsychotic-induced side effects // Dialogues Clin. Neurosci. - 2009. - Vol. 11(4). - P. 405-415.
38. Lencz T., Robinson D.G., Napolitano B., Sevy S., Kane J.M., Goldman D., Malhotra A.K. DRD2 promoter region variation predicts antipsychotic-induced weight gain in first episode schizophrenia // Pharmacogenet Genomics. - 2010. - Vol. 20(9). - P. 569-572.
39. Lett T.A., Wallace T.J., Chowdhury N.I., Tiwari A.K., Kennedy J.L., Müller D.J. Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications // Mol. Psychiatry. - 2012. - Vol. 17(3). - P. 242-266.
40. Lieberman J.A., Stroup T.S., McEvoy J.P. et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. // N. Engl. J. Med. - 2005. - Vol. 353(12). - P. 1209-1223.
41. Liu Y.R., Loh E.W., Lan T.H., Chen S.F., Yu Y.H., Chang Y.H. et al. ADRA1A gene is associated with BMI in chronic schizophrenia patients exposed to antipsychotics // J. Pharmacogenomics. - 2010. - Vol. 10. - P. 30-39.
42. Lubrano-Berthelier C., Cavazos M., Dubern B., Shapiro A., Stunff C.L., Zhang S. et al. Molecular genetics of human obesityassociated MC4R mutations // Ann NY Acad Sci. - 2003. - Vol. 994. - 49-57.
43. Malhotra A.K., Correll C.U., Chowdhury N.I., Müller D.J., Gregersen P.K., Lee A.T., Tiwari A.K., Kane J.M., Fleischhacker W.W., Kahn R.S., Ophoff R.A., Meltzer H.Y., Lencz T., Kennedy J.L. Association between common variants near the melanocortin
44. receptor gene and severe antipsychotic drug-induced weight gain // Arch Gen Psychiatry. - 2012. - Vol. 69(9). - P. 904-12.
45. Marland G.R., Cash K. Long-term illness and patterns of medicine taking: are people with schizophrenia a unique group? J. Psychiatr. Ment. Health. Nurs. - 2001. - Vol. 8(3). - P. 197-204.
46. Martynikhin I., Sokolian N., Neznanov N., Tanyanskiy D., Denisenko. A., Rotar O., Solntsev V., Konradi A., Shlyakhto E. Risk of metabolic syndrome in patients with schizophrenia: comparative study with population of bank employees in russia // Archives of Psychiatry and Psychotherapy. - 2013. - Т. 15. - № 2. - С. 15-20.
47. Marzolini C., Paus E., Buclin T., Kim R.B. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance // Clin. Pharmacol. Ther. - 2004. - Vol. 75(1). - P. 13-33.
48. Meyre D., Delplanque J., Chevre J.C., Lecoeur C., Lobbens S., Gallina S. et al. Genome-wide association study for early-onset and morbid adult obesity identifies three new risk loci in European populations // Nat. Genet. - 2009. - Vol. 41. - P. 157-159.
49. Mou X.D., Zhang Z.J., Zhang X.R., Shi J.B., Sun J. -2548G/A functional polymorphism in the promoter region of leptin gene and antipsychotic agent-induced weight gain in schizophrenic patients: a study of nuclear family-based association // Zhong Nan Da Xue Xue Bao Yi Xue Ban. - 2008. - Vol. 33(4). - P. 316-320.
50. Mu ller D.J., Klempan T.A., De Luca V., Sicard T., Volavka J., Czobor P. et al. The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophrenia // Neurosci. Lett. - 2005. - Vol. 379. - P. 81-89.
51. Mulder H., Cohen D., Scheffer H., Gispen-de Wied C., Arends J., Wilmink F.W., Franke B., Egberts A.C. HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia: a replication study // J. Clin. Psychopharmacol. - Feb. - Vol. 29(1). - P. 16-20.
52. Müller D.J., Zai C.C., Sicard M., Remington E., Souza R.P., Tiwari A.K., Hwang R., Likhodi O., Shaikh S., Freeman N., Arenovich T., Heinz A., Meltzer H.Y., Lieberman J.A., Kennedy J.L. Systematic analysis of dopamine receptor genes (DRD1-DRD5) in antipsychotic-induced weight gain // Pharmacogenomics J. - 2012. - Vol. 12(2). - P. 156-164.
53. Musil R., Spellmann I., Riedel M., Dehning S., Douhet A., Maino K. et al. SNAP-25 gene polymorphisms and weight gain in schizophrenic patients // J. Psychiatr. Res. - 2008. - Vol. 42. - P. 963-970.
54. Nagamatsu S., Nakamichi Y., Yamamura C., Matsushima S., Watanabe T., Ozawa S. et al. Decreased expression of t-SNARE, syntaxin 1, and SNAP-25 in pancreatic beta-cells is involved in impaired insulin secretion from diabetic GK rat islets: restoration of decreased t-SNARE proteins improves impaired insulin secretion // Diabetes. - 1999. - Vol. 48. - P. 2367-2373.
55. Nnadi C.U., Malhotra A.K. Individualizing antipsychotic drug therapy in schizophrenia: the promise of pharmacogenetics // Curr. Psychiatry Rep. - 2007. - Vol. 9(4). - P. 313-318.
56. Opgen-Rhein C., Brandl E.J., Müller D.J., Neuhaus A.H., Tiwari A.K., Sander T., Dettling M. Association of HTR2C, but not LEP or INSIG2, genes with antipsychotic-induced weight gain in a German sample // Pharmacogenomics. - 2010 Jun. - Vol. 11(6). - P. 773-80.
57. Park Y.-M., Chung Y.-C., Lee S.-H., Lee K.-J., Kim H., Choi J.-E. et al. G-protein beta3 subunit gene 825C/T polymorphism is not associated with olanzapine-induced weight gain in Korean schizophrenic patients // Psychiatry Invest. - 2009. - Vol. 6 - P. 39-43.
58. Park Y.M., Chung Y.C., Lee S.H., Lee K.J., Kim H., Byun Y.C., Lim S.W., Paik J.W., Lee H.J. Weight gain associated with the a2a-adrenergic receptor 1291C/G polymorphism and olanzapine treatment // Am. J. Med. Genet. B Neuropsychiatr. Genet. - 2006. - Vol. 141B. - P. 394-397.
59. Perez-Iglesias R., Mata I., Amado J.A., Berja A., Garcia-Unzueta M.T., Martinez Garcia O., Arranz M.J., Vazquez-Barquero J.L., Crespo-Facorro B. Effect of FTO, SH2B1, LEP, and LEpR polymorphisms on weight gain associated with antipsychotic treatment // J. Clin. Psychopharmacol. - 2010 Dec. - Vol. 30(6). - P. 661-666.
60. Popp J., Leucht S., Heres S., Steimer W. DRD4 48 bp VNTR but not 5-HT 2C Cys23Ser receptor polymorphism is related to antipsychotic-induced weight gain // Pharmacogenomics J. - 2009 Feb. - Vol. 9(1). - P. 71-77.
61. Risselada A.J., Mulder H., Heerdink E.R., Egberts T.C. Pharmacogenetic testing to predict antipsychotic-induced weight gain: a systematic review // Pharmacogenomics. - 2011 Aug. - Vol. 12(8). - P. 1213-1227.
62. Risselada A.J., Vehof J., Bruggeman R., Wilffert B., Cohen D., A Hadithy A.F., Arends J., Mulder H. Association between the 1291-C/G polymorphism in the adrenergic a-2a receptor and the metabolic syndrome // J. Clin. Psychopharmacol. - 2010. - Vol. 30(6). - P. 667-671.
63. Ruano G., Goethe J.W., Caley C., Woolley S., Holford T.R., Kocherla M., Windemuth A., de Leon J. Physiogenomic comparison of weight profiles of olanzapine- and risperidone-treated patients // Mol Psychiatry. - 2007 May. - Vol. 12(5). - P. 474-482.
64. Sentissi O., Epelbaum J., Olié J.P., Poirier M.F. Leptin and ghrelin levels in patients with schizophrenia during different antipsychotics treatment: a review // Schizophr. Bull. - 2008 Nov. - Vol. 34(6). - P. 1189-1199.
65. Sicard M.N., Zai C.C., Tiwari A.K., Souza R.P., Meltzer H.Y., Lieberman J.A., Kennedy J.L., Müller D.J. Polymorphisms of the HTR2C gene and antipsychotic-induced weight gain: an update and meta-analysis // Pharmacogenomics. - 2010 Nov. - Vol. 11(11). - P. 1561-1571.
66. Sickert L., Müller D.J., Tiwari A.K., Shaikh S., Zai C., De Souza R., De Luca V., Meltzer H.Y., Lieberman J.A., Kennedy J.L. Association of the a2A adrenergic receptor -1291 C/G polymorphism and antipsychotic-induced weight gain in European Amercans // Pharmacogenomics. - 2009. - Vol. 10. - P. 1169-1176.
67. Siffert W. G-protein beta3 subunit 825T allele and hypertension // Curr. Hypertens. Rep. - 2003. - Vol. 5. - P. 47-53.
68. Smith R.C., Rachakonda S., Dwivedi S., Davis J.M. Olanzapine and risperidone effects on appetite and ghrelin in chronic schizophrenic patients // Psychiatry Res. - 2012 Oct.- Vol. 199(3). - P. 159-163.
69. Souza R.P., Tiwari A.K., Chowdhury N.I., Ceddia R.B., Lieberman J.A., Meltzer H.Y., Kennedy J.L., Müller D.J. Association study between variants of AMP-activated protein kinase catalytic and regulatory subunit genes with antipsychotic-induced weight gain // J. Psychiatr. Res. - 2012 Apr. - Vol. 46(4). - P. 462-468.
70. Srivastava V., Deshpande S.N., Nimgaonkar V.L., Lerer B., Thelma B. Genetic correlates of olanzapine-induced weight gain in schizophrenia subjects from north India: role of metabolic pathway genes // Pharmacogenomics. -2008 Aug. - Vol. 9(8). - P. 1055-1068.
71. Steck H. Extrapyramidal and diencephalic syndrome in the course of largactil and serpasil treatments // Ann Med Psychol (Paris). - 2006. - Vol. 112. - P. 737-744.
72. Stroup T.S., Lieberman J.A., McEvoy J.P., Swartz M.S., Davis S.M., Rosenheck R.A., Perkins D.O., Keefe R.S., Davis C.E., Severe J., Hsiao J.K. Effectiveness of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Patients With Chronic Schizophrenia Following Discontinuation of a Previous Atypical Antipsychotic // Am. J. Psychiatry. - 2006 Apr. - Vol. 163(4). - P. 611-22.
73. Sudhof T.C. The synaptic vesicle cycle // Ann Rev Neurosci. - 2004. - Vol. 27. - P. 509-54
74. Takeuchi S., Katoh T., Yamauchi T., Kuroda Y. ADRB3 polymorphism associated with BMI gain in Japanese men // Exp Diabetes Res. - 2012. - Vol. 2012. - P. 1-5.
75. Tandon R., Belmaker R.H., Gattaz W.F., Lopez-Ibor J.J. Jr., Okasha A., Singh B., Stein D.J., Olie J.P., Fleischhacker W.W., Moeller H.J. World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia // Schizophr. Res. - 2008. - Vol. 100(1-3). - P. 20-38.
76. Templeman L.A., Reynolds G.P., Arranz B., San L. Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis // Pharmacogenet Genomics. - 2005 Apr. - Vol. 15(4). - P. 195-200.
77. Thomas P., Srivastava V., Singh A., Mathur P., Nimgaonkar V.L., Lerer B., Thelma B.K., Desh-pande S.N. Correlates of response to Olanzapine in a North Indian schizophrenia sample // Psychiatry Res. - 2008. - Vol.161 (3). - P. 275-283.
78. Thorleifsson G., Walters G.B., Gudbjartsson D.F., Steinthorsdottir V., Sulem P., Helgadottir A., Styrkarsdottir U., Gretarsdottir S., Thorlacius S., Jonsdottir I. et al. Genome-wide association yields new sequence variants at seven loci that associate with measures of obesity // Nat. Genet. - 2009 Jan. - Vol. 41(1). - P. 18-24.
79. Tiwari A.K., Brandl E.J., Weber C., Likhodi O., Zai C.C., Hahn M.K., Lieberman J.A., Meltzer H.Y., Kennedy J.L., Müller D.J. Association of a functional polymorphism in neuropeptide Y with antipsychotic-induced weight gain in schizophrenia patients // J. Clin. Psychopharmacol. - 2013 Feb. - Vol. 33(1). - P. 11-17.
80. Tiwari A.K., Zai C.C., Likhodi O, Lisker A, Singh D, Souza R.P., Batra P., Zaidi S.H., Chen S., Liu F., Puls I., Meltzer H.Y, Lieberman J.A., Kennedy J.L., Müller D.J. A common polymorphism in the cannabinoid receptor 1 (CNR1) gene is associated with antipsychotic-induced weight gain in Schizophrenia // Neuropsychopharmacology. - 2010 May. - Vol. 35(6). - P. 1315-1324.
81. Tsai A., Liou Y.J., Hong C.J., Wu C.L., Tsai S.J., Bai Y.M. Association study of brain-derived neurotrophic factor gene polymorphisms and body weight change in schizophrenic patients under long-term atypical antipsychotictreatment // Neuromolecular Med. - 2011 Dec. - Vol. 13(4). - P. 328-333.
82. Tsai S.J., Yu Y.W., Lin C.H., Wang Y.C., Chen J.Y., Hong C.J. Association study of adrenergic beta3 receptor (Trp64Arg) and G-protein beta3 subunit gene (C825T) polymorphisms and weight change during clozapine treatment // Neuropsychobiology. - 2004. - Vol. 50(1). - P. 37-40.
83. Ujike H., Nomura A., Morita Y., Morio A., Okahisa Y., Kotaka T., Kodama M., Ishihara T., Kuroda S. Multiple genetic factors in olanzapine-induced weight gain in schizophrenia patients: a cohort study // J. Clin. Psychiatry. - 2008 Sep. - Vol. 69(9). - P 14161422.
84. Vehof J., Risselada A.J., Al Hadithy A.F., Burger H., Snieder H., Wilffert B., Arends J., Wunderink L., Knegtering H., Wiersma D., Cohen D., Mulder H., Bruggeman R. Association of genetic variants of the histamine H1 and muscarinic M3 receptors with BMI and HbA1c values in patients on antipsychotic medication // Psychopharmacology (Berl). - 2011 Jul. - Vol. 216(2). - P. 257-265.
85. Vetti H.H., Molven A., Eliassen A.K. et al. Is pharmacogenetic CYP2D6 testing useful? // Tidsskr Nor Laegefore. - 2010. - Vol. 130(22). - P. 2224-2228.
Рецензия
Для цитирования:
Насырова Р.Ф., Сивакова Н.А., Иващенко Д.В., Сосин Д.Н., Ершов Е.Е., Сосина К.А., Ахметова Л.Ш., Воликова О.В., Бейбалаева Т.З., Незнанов Н.Г. Фармакогенетика антипсихотик-индуцированных метаболических нарушений: актуальное состояние проблемы. Обозрение психиатрии и медицинской психологии имени В.М.Бехтерева. 2016;(3):67-80.
For citation:
Nasyrova R.F., Sivakova N.A., Ivashchenko D.V., Sosin D.N., Ershov E.E., Sosina K.A., Akhmetova L.S., Volikova O.V., Beybalayeva T.Z., Neznanov N.G. Pharmacogenetics of antipsychotic-induced metabolic disturbances: state-of-the-art. V.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY. 2016;(3):67-80. (In Russ.)
Просмотров: 467
Послать статью по эл. почте 